Report Overview:
Oral asthma medications play a critical role in managing asthma, particularly for patients who require additional control beyond inhaled therapies or who have difficulty using inhalers. These medications include leukotriene modifiers (e.g., montelukast), which help reduce inflammation and bronchoconstriction by blocking leukotrienes, and oral corticosteroids (e.g., prednisone), used for short-term management of severe exacerbations due to their potent anti-inflammatory effects.
This report provides a deep insight into the global Oral Asthma Medications market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
Market Value:
The global Oral Asthma Medications market size was estimated at USD 652 million in 2024 and is projected to reach USD 1015.89 million by 2032, exhibiting a CAGR of 5.70% during the forecast period.
North America Oral Asthma Medications market size was estimated at USD 186.90 million in 2024, at a CAGR of 4.89% during the forecast period of 2024 through 2032.
CAGR of 5.70% (2025 – 2032)
By Types:
•Tablets
Capsules
By Applications:
Anti-inflammatory
Bronchodilators
Combination Therapy
Key players include:
•Teva Pharmaceutical
•GSK
•Merck
•Roche
•AstraZeneca
•Boehringer Ingelheim International
•Sanofi
•Including or Excluding key companies relevant to your analysis.
